Plans-Rubió season. To achieve a 100% vaccination rate in patients with COPD, all patients with COPD registered in health insurance companies and attended in health centers and specialized clinics should be vaccinated during the immunization period (October–December in Northern hemisphere and April–May in Southern hemisphere). Antiviral therapies could be used as an adjunct to vaccination, since they could reduce the duration and complications of inﬂuenza when administered within two days of illness onset. Research is necessary for new antiviral therapies that could prevent inﬂuenza with cost-effectiveness similar to the inﬂuenza vaccine. References Ahmed AH, Nicholson KG, Nguyen-van Tam JS, et al. 1997. Effectiveness of inﬂuenza vaccine in reducing hospital admissions during the 1989–90 epidemic. Epidemiol Infect, 118:27–33. [ACP] American College of Physicians. 1996. Guide for adult immuniza- tion. Philadelphia: ACP. [ALAACRC] American Lung Association Asthma Clinical Research Cent- ers. 2001. The safety of inactivated inﬂuenza vaccine in adults and children with asthma. N Engl J Med, 345:1529–36. Anthonisen NR. 1989. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis, 140:S95–S99. Anthonisen NR. 2002. Bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med, 347:526–7. Barker WH. 1986. Excess pneumonia and inﬂuenza associated hospitaliza- tion during inﬂuenza epidemics in the United States, 1970–78. Am J Public Health, 76:761–5. Barker WH, Mullooly JP. 1980. Impact of epidemic type A inﬂuenza in a deﬁned adult population. Am J Epidemiol, 112:798–811. Barker WH, Mullooly JP. 1982. Pneumonia and inﬂuenza deaths during epidemics: implications for prevention. Arch Intern Med, 142:85–9. Bowles SK, Lee W, Simor AE, et al. 2002. Use of oseltamivir during in- ﬂuenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc, 50:608–16. Bridges CB, Thompson WW, Meltzer MI, et al. 2000. Effectiveness and cost-beneﬁt of inﬂuenza vaccination of healthy working adults: a ran- domized controlled trial. JAMA, 284:1655–60. [CDC] Centers for Disease Control and Prevention. 2004. Assessment of the effectiveness of the 2003–04 inﬂuenza vaccine among children and adults-Colorado, 2003. MMWR Morb Mortal Wkly Rep, 53:707–710. [CDC] Centers for Disease Control and Prevention. 2006. Prevention and con- trol of inﬂuenza. MMWR Morb Mortal Wkly Rep, 55 (RR-10):1–42. [CMMS] Centers for Medicare and Medicaid Services. 2002. Medicare and Medicaid programs; conditions of participation: immunization standards for hospitals, long-term care facilities, and home health agencies. Final rule with comment period. Federal Register, 67:61808–14. Clements DA, Langdon L, Bland C, et al. 1995. Inﬂuenza A vaccine de- creases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med, 149:1113–17. Connors AP, Dawson NV, Thomas C, et al. 1996. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Resp Crit Med, 154:959–67. Cooper NJ, Sutton AJ, Abrams KR, et al. 2003. Effectiveness of neurami- nidase inhibitors in treatment and prevention of inﬂuenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ, 326:1235–41. Cox NJ, Subbarao K. 1999. Inﬂuenza. Lancet, 354:1277–82. Cox NJ, Fuller F, Kaverin et al. 2000. Orthomyxoviridae. In: van Regenmortel MHV, Fauquet CM, Bishop DHL et al (eds). Virus taxonomy: Classiﬁcation and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, pp 585–97. 52 Demicheli V, Jefferson T, Rivetti D, et al. 2000. Prevention and early treat- ment of inﬂuenza in healthy adults. Vaccine, 18:957–1030. Edwards KM, Dupont WD, Westrich MK, et al. 1994. A randomized control- led trial of COLD-adapted and inactivated vaccines for the prevention of inﬂuenza A disease. J Infect Dis, 169:68–76. Fedson DS, Wajda A, Nicol JP, et al. 1992. Disparity between inﬂuenza vaccination rates and risks for inﬂuenza-associated hospital discharge and death in Manitoba in 1982–1983. Ann Intern Med, 116:550–5. Fukuda K, Levandowski RA, Bridges CB, et al. 2004. Inactivated inﬂuenza vaccines. In: Plotkin SA, Orenstein WA (eds). Vaccines. Philadelphia: Saunders, pp 339–65. Glezen WP. 1982. Serious morbidity and mortality associated with inﬂuenza epidemics. Epidemiol Rev, 4:25–40. Glezen WP, Decker M, Perrotta DM. 1987. Survey of underlying condi- tions of persons hospitalized with acute respiratory disease during inﬂuenza epidemics in Houston, 1978–1981. Am Rev Respir Dis, 136:550–5. Glezen WP, Greenberg SB, Atmar RL, et al. 2000. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA, 283:499–505. Gross PA, Hermogenes AW, Sacks HS, et al. 1995. The efﬁcacy of inﬂuenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med, 123:518–27. Grotto I, Mandel Y, Green MS, et al. 1998. Inﬂuenza vaccine efﬁcacy in young, healthy adults. Clin Infect Dis, 26:913–17. Guay DR. 1994. Amantadine and rimantadine prophylaxis of inﬂuenza A in nursing homes. A tolerability perspective. Drugs Aging, 5:8–19. Harper SA, Fukuda K, Uyeki TM, et al; Advisory Committee on Immuniza- tion Practices (ACIP) Centers for Disease Control and Prevention. 2005. Prevention and control of inﬂuenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 54(No. RR-8):1–40. Hayden FG, Hay AJ. 1992. Emergence and transmission of inﬂuenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol, 176:119–30. Hayden FG, Osterhaus AD, Treanor JJ, et al. 1997. Efﬁcacy and safety of the neuraminidase inhibitor zanamivir in the treatment of inﬂu- enza virus infections. GG167 Inﬂuenza Study Group. N Engl J Med, 337:874–80. Heikkinen T, Ruuskanen O, Waris M, et al. 1991. Inﬂuenza vaccination in the prevention of acute otitis media in children. Am J Dis Child, 145:445–48. Hoberman A, Greenberg DP, Paradise JL, et al. 2003. Effectiveness of inactivated inﬂuenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA, 290:1608–16. Hurd S. 2000. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest, 117(suppl 2):1S–4S. Izurieta HS, Thompson WW, Kramarz P, et al. 2000. Inﬂuenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med, 342:232–9. Jackson HC, Roberts N, Wang ZM, et al. 2000. Management of inﬂuenza: use of new antivirals and resistance in perspective. Clin Drug Invest, 20:447–54. Jefferson T, Demicheli V, Deeks J, et al. 2000. Neuraminidase inhibitors for preventing and treating inﬂuenza in healthy adults. Cochrane Database Syst Rev, 2:CD001265. Kaplan JE, Katona P, Hurwitz ES, et al. 1982. Guillain-Barre syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with inﬂuenza vaccination. JAMA, 248:698–700. Kilbourne E. 1987. Inﬂuenza. New York, NY: Plenum Medical Book Company. Lawson F, Baker V, Au D, et al. 2000. Standing orders for inﬂuenza vac- cination increased vaccination rates in inpatient settings compared with community rates. J Gerontol A Biol Sci Med Sci, 55:M522–M526. Lee C, Loeb M, Phillips A, et al. 2000. Zanamivir use during transmission of amantadine-resistant inﬂuenza A in a nursing home. Infect Control Hosp Epidemiol, 21:700–4. International Journal of COPD 2007:2(1)